By RTT News,
July 09, 2014, 07:25:00 AM EDT
(RTTNews.com) - Lexicon Pharmaceuticals, Inc. ( LXRX ) Wednesday said the charity organization Juvenile Diabetes Research Foundation will fund a Phase 2 study to test LX4211 on subjects younger than 30 years with type 1 diabetes.
LX4211 is an oral, first-in-class drug that is designed to bring down blood glucose levels through two insulin-independent mechanisms.
The randomized, double-masked study's primary objective is to demonstrate the superiority of LX4211 against placebo as adjunct to insulin treatment on HbA1c reduction at 12 weeks.
Reduced variability in blood glucose levels and lower insulin needs are some of the secondary endpoints.
In a previous Phase 2 clinical trial of LX4211 in type 1 diabetes, LX4211 treatment was shown to reduce mean HbA1c by 0.55 percent compared to a reduction of only 0.06 percent with placebo (p=0.002) over a four-week treatment period, the company said in a statement.
"The results from our previous Phase 2 study of LX4211 in type 1 diabetes have encouraged us to also explore its potential application in this younger population for whom managing glucose variability is an especially difficult challenge and in which the significant majority are unable to achieve HbA1c targets," said Pablo Lapuerta, Lexicon's chief medical officer.
JDRF, an organization whose goal is to fund type 1 diabetes research, sponsors $568 million in scientific research in seventeen countries.
For comments and feedback: contact firstname.lastname@example.org